Trials / Completed
CompletedNCT02304484
Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 770 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to characterize the safety and tolerability of long-term administration of evolocumab in adults with known coronary artery disease and hypercholesterolemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Evolocumab | Administered by subcutaneous injection once a month |
Timeline
- Start date
- 2014-11-24
- Primary completion
- 2018-03-09
- Completion
- 2018-03-09
- First posted
- 2014-12-02
- Last updated
- 2019-03-19
- Results posted
- 2019-03-19
Locations
126 sites across 29 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Czechia, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, Norway, Poland, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom
Source: ClinicalTrials.gov record NCT02304484. Inclusion in this directory is not an endorsement.